This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barnard, J. P.
Right arrow Articles by Friedlander, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barnard, J. P.
Right arrow Articles by Friedlander, A. M.

 Previous Article  |  Next Article 

Infection and Immunity, February 1999, p. 562-567, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Vaccination against Anthrax with Attenuated Recombinant Strains of Bacillus anthracis That Produce Protective Antigen

John P. Barnard,dagger and Arthur M. Friedlander*

Division of Bacteriology, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21701-5011

Received 6 July 1998/Returned for modification 10 August 1998/Accepted 4 November 1998

The protective efficacy of several live, recombinant anthrax vaccines given in a single-dose regimen was assessed with Hartley guinea pigs. These live vaccines were created by transforming Delta ANR and Delta Sterne, two nonencapsulated, nontoxinogenic strains of Bacillus anthracis, with four different recombinant plasmids that express the anthrax protective antigen (PA) protein to various degrees. This enabled us to assess the effect of the chromosomal background of the strain, as well as the amount of PA produced, on protective efficacy. There were no significant strain-related effects on PA production in vitro, plasmid stability in vivo, survival of the immunizing strain in the host, or protective efficacy of the immunizing infection. The protective efficacy of the live, recombinant anthrax vaccine strains correlated with the anti-PA antibody titers they elicited in vivo and the level of PA they produced in vitro.

* Corresponding author. Mailing address: USAMRIID, 1425 Porter Street, Fort Detrick, MD 21702-5011. Phone: (301) 619-7341. Fax: (301) 619-2152. E-mail: friedlan{at}ncifcrf.gov.

dagger Present address: Department of Microbiology, State University of New York, Buffalo, NY 14214-3005.

Infection and Immunity, February 1999, p. 562-567, Vol. 67, No. 2
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Gauthier, Y. P., Tournier, J.-N., Paucod, J.-C., Corre, J.-P., Mock, M., Goossens, P. L., Vidal, D. R. (2009). Efficacy of a Vaccine Based on Protective Antigen and Killed Spores against Experimental Inhalational Anthrax. Infect. Immun. 77: 1197-1207 [Abstract] [Full Text]  
  • Samant, S., Hsu, F.-F., Neyfakh, A. A., Lee, H. (2009). The Bacillus anthracis Protein MprF Is Required for Synthesis of Lysylphosphatidylglycerols and for Resistance to Cationic Antimicrobial Peptides. J. Bacteriol. 191: 1311-1319 [Abstract] [Full Text]  
  • Kwok, W. W., Yang, J., James, E., Bui, J., Huston, L., Wiesen, A. R., Roti, M. (2008). The Anthrax Vaccine Adsorbed Vaccine Generates Protective Antigen (PA)-Specific CD4+ T Cells with a Phenotype Distinct from That of Naive PA T Cells. Infect. Immun. 76: 4538-4545 [Abstract] [Full Text]  
  • Bozue, J., Cote, C. K., Moody, K. L., Welkos, S. L. (2007). Fully Virulent Bacillus anthracis Does Not Require the Immunodominant Protein BclA for Pathogenesis. Infect. Immun. 75: 508-511 [Abstract] [Full Text]  
  • Gat, O., Grosfeld, H., Ariel, N., Inbar, I., Zaide, G., Broder, Y., Zvi, A., Chitlaru, T., Altboum, Z., Stein, D., Cohen, S., Shafferman, A. (2006). Search for Bacillus anthracis Potential Vaccine Candidates by a Functional Genomic-Serologic Screen. Infect. Immun. 74: 3987-4001 [Abstract] [Full Text]  
  • Zomber, G., Reuveny, S., Garti, N., Shafferman, A., Elhanany, E. (2005). Effects of Spontaneous Deamidation on the Cytotoxic Activity of the Bacillus anthracis Protective Antigen. J. Biol. Chem. 280: 39897-39906 [Abstract] [Full Text]  
  • Aloni-Grinstein, R., Gat, O., Altboum, Z., Velan, B., Cohen, S., Shafferman, A. (2005). Oral Spore Vaccine Based on Live Attenuated Nontoxinogenic Bacillus anthracis Expressing Recombinant Mutant Protective Antigen. Infect. Immun. 73: 4043-4053 [Abstract] [Full Text]  
  • Marcus, H., Danieli, R., Epstein, E., Velan, B., Shafferman, A., Reuveny, S. (2004). Contribution of Immunological Memory to Protective Immunity Conferred by a Bacillus anthracis Protective Antigen-Based Vaccine. Infect. Immun. 72: 3471-3477 [Abstract] [Full Text]  
  • Musson, J. A., Walker, N., Flick-Smith, H., Williamson, E. D., Robinson, J. H. (2003). Differential Processing of CD4 T-cell Epitopes from the Protective Antigen of Bacillus anthracis. J. Biol. Chem. 278: 52425-52431 [Abstract] [Full Text]  
  • Williams, R. C., Rees, M. L., Jacobs, M. F., Pragai, Z., Thwaite, J. E., Baillie, L. W. J., Emmerson, P. T., Harwood, C. R. (2003). Production of Bacillus anthracis Protective Antigen Is Dependent on the Extracellular Chaperone, PrsA. J. Biol. Chem. 278: 18056-18062 [Abstract] [Full Text]  
  • Spencer, R C (2003). Bacillus anthracis. J. Clin. Pathol. 56: 182-187 [Abstract] [Full Text]  
  • Gat, O., Inbar, I., Aloni-Grinstein, R., Zahavy, E., Kronman, C., Mendelson, I., Cohen, S., Velan, B., Shafferman, A. (2003). Use of a Promoter Trap System in Bacillus anthracis and Bacillus subtilis for the Development of Recombinant Protective Antigen-Based Vaccines. Infect. Immun. 71: 801-813 [Abstract] [Full Text]  
  • Reuveny, S., White, M. D., Adar, Y. Y., Kafri, Y., Altboum, Z., Gozes, Y., Kobiler, D., Shafferman, A., Velan, B. (2001). Search for Correlates of Protective Immunity Conferred by Anthrax Vaccine. Infect. Immun. 69: 2888-2893 [Abstract] [Full Text]  
  • Cohen, S., Mendelson, I., Altboum, Z., Kobiler, D., Elhanany, E., Bino, T., Leitner, M., Inbar, I., Rosenberg, H., Gozes, Y., Barak, R., Fisher, M., Kronman, C., Velan, B., Shafferman, A. (2000). Attenuated Nontoxinogenic and Nonencapsulated Recombinant Bacillus anthracis Spore Vaccines Protect against Anthrax. Infect. Immun. 68: 4549-4558 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»